These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 23011396

  • 1. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.
    J Acquir Immune Defic Syndr; 2013 Jan 01; 62(1):60-6. PubMed ID: 23011396
    [Abstract] [Full Text] [Related]

  • 2. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.
    J Acquir Immune Defic Syndr; 2007 Jun 01; 45(2):201-5. PubMed ID: 17414932
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
    Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.
    Br J Clin Pharmacol; 2011 Dec 01; 72(6):940-7. PubMed ID: 21649692
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T, HIV-NAT 146 Study Team.
    Pediatr Infect Dis J; 2014 Dec 01; 33(12):e316-9. PubMed ID: 24983717
    [Abstract] [Full Text] [Related]

  • 5. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
    Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.
    Antimicrob Agents Chemother; 2011 Dec 01; 55(12):5746-52. PubMed ID: 21930880
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
    Moltó J, Estévez JA, Miranda C, Cedeño S, Clotet B, Valle M.
    Br J Clin Pharmacol; 2016 Dec 01; 82(6):1528-1538. PubMed ID: 27447851
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
    Punyawudho B, Thammajaruk N, Ruxrungtham K, Avihingsanon A.
    Int J Antimicrob Agents; 2017 Mar 01; 49(3):327-332. PubMed ID: 28109702
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.
    Antimicrob Agents Chemother; 2007 Apr 01; 51(4):1431-9. PubMed ID: 17296738
    [Abstract] [Full Text] [Related]

  • 9. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.
    AIDS; 2005 Apr 29; 19(7):685-94. PubMed ID: 15821394
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.
    HIV Med; 2013 Aug 29; 14(7):401-9. PubMed ID: 23433482
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, López Galera RM, Ribera Pascuet E, Domínguez-Gil Hurlé A, García Sánchez MJ.
    Ther Drug Monit; 2011 Oct 29; 33(5):573-82. PubMed ID: 21912331
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.
    Antivir Ther; 2006 Oct 29; 11(1):53-62. PubMed ID: 16518960
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
    Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.
    J Antimicrob Chemother; 2009 Jun 29; 63(6):1233-43. PubMed ID: 19329800
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.